NYSE American: APUS

Apimeds Pharmaceuticals US, Inc. (APUS)

Apimeds Pharmaceuticals US, Inc. is a public company that reports to the U.S. Securities and Exchange Commission and trades on NYSE American under the ticker APUS. Bright Analyst brings its financial statements, SEC filings, stock performance, news and peer comparisons together in one place, with AI analysis throughout.

Key facts

Ticker symbol
APUS
Exchange
NYSE American
SEC CIK
1894525
Official filings
SEC EDGAR

Research APUS

  • Profile — Business description, headquarters, subsidiaries and corporate identifiers.
  • Financials — Income statement, balance sheet and cash flow from 10-K and 10-Q filings.
  • SEC Filings — Every 10-K, 10-Q and 8-K, readable inline with AI analysis.
  • Stock Analysis — Price chart, returns, technical indicators and related companies.
  • News — Latest headlines and press coverage.
  • Material Contracts — Material agreements filed as exhibits to SEC reports.
  • Benchmark — Stock performance against the S&P 500, Nasdaq-100 and Dow (through SPY, QQQ and DIA) and economic indicators.
  • Peer Comparison — Side-by-side financial ratios against industry peers.

Frequently asked questions

What is Apimeds Pharmaceuticals US, Inc.'s stock ticker?

Apimeds Pharmaceuticals US, Inc. trades under the ticker symbol APUS on NYSE American. Its SEC Central Index Key (CIK) is 1894525.

Where can I read Apimeds Pharmaceuticals US, Inc.'s SEC filings?

The APUS SEC Filings page lists the 10-K annual reports, 10-Q quarterly reports and 8-K current reports Apimeds Pharmaceuticals US, Inc. has filed, with AI analysis. The original documents are also on SEC EDGAR.

How can I analyze APUS's financial statements?

The APUS Financials page shows Apimeds Pharmaceuticals US, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly, taken from its XBRL filings, with an AI analysis of each statement.

How does APUS compare with its peers and the market?

The APUS Peer Comparison page lines Apimeds Pharmaceuticals US, Inc. up against industry peers on valuation, growth and profitability ratios, and the Benchmark page compares its stock with the S&P 500, the Nasdaq-100 and the Dow.

For information only — not investment advice.